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Abstract 
An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular 
risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagula-
tion proteins, is composed of a skeleton of fibrin fibres with cellular elements embedded in this network. Diabetes is 
characterised by quantitative and qualitative changes in coagulation proteins, which collectively increase resistance 
to fibrinolysis, consequently augmenting thrombosis risk. Current long-term therapies to prevent arterial occlusion in 
diabetes are focussed on anti-platelet agents, a strategy that fails to address the contribution of coagulation proteins 
to the enhanced thrombotic milieu. Moreover, antiplatelet treatment is associated with bleeding complications, 
particularly with newer agents and more aggressive combination therapies, questioning the safety of this approach. 
Therefore, to safely control thrombosis risk in diabetes, an alternative approach is required with the fibrin network 
representing a credible therapeutic target. In the current review, we address diabetes-specific mechanistic pathways 
responsible for hypofibrinolysis including the role of clot structure, defects in the fibrinolytic system and increased 
incorporation of anti-fibrinolytic proteins into the clot. Future anti-thrombotic therapeutic options are discussed with 
special emphasis on the potential advantages of modulating incorporation of the anti-fibrinolytic proteins into fibrin 
networks. This latter approach carries theoretical advantages, including specificity for diabetes, ability to target a 
particular protein with a possible favourable risk of bleeding. The development of alternative treatment strategies to 
better control residual thrombosis risk in diabetes will help to reduce vascular events, which remain the main cause of 
mortality in this condition.
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Background
Diabetes is becoming the epidemic of the twenty first 
century with more than 1.5 million deaths worldwide 
directly attributed to this condition in 2012 (http://www.
who.int). Despite advances in therapy, cardiovascular 
disease (CVD) remains the main cause of morbidity and 
mortality in individuals with diabetes. The risk of vas-
cular complications is doubled in diabetes, resulting in 
significant reduction in life expectancy [1, 2]. Moreover, 
following a vascular event, the outcome in patients with 
diabetes is worse compared with individuals with normal 
glucose metabolism, regardless of the therapeutic strat-
egy used in the acute stage [3–7]. There are two key rea-
sons for the adverse vascular outcome in patients with 
diabetes. The first is related to more extensive vascular 
pathology and the second involves an enhanced throm-
botic environment [8]. There are two main types of dia-
betes, one is characterised by insulin deficiency, termed 
type 1 diabetes (T1DM), and the other, type 2 diabetes 
(T2DM), arising mainly due to insulin resistance second-
ary to increased prevalence of obesity. However, the two 
conditions can overlap as a significant proportion of indi-
viduals with T1DM develop a phenotype seen in T2DM, 
making them fall into a new category termed double dia-
betes [9]. Equally, longer duration of T2DM can lead to 
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insulin deficiency, making these individuals similar to 
T1DM patients.
Blood clot formation occurs secondary to interactions 
between the cellular and protein arms of coagulation, 
resulting in a network of fibrin fibres populated by vari-
ous blood cells. Diabetes is characterised by enhanced 
activation of platelets as well as the formation of compact 
fibrin networks that are resistant to fibrinolysis [10–15], 
consequently increasing thrombosis risk.
Although the presence of a prothrombotic environment 
in diabetes is well documented, current anti-thrombotic 
treatment strategies aiming to reduce vascular risk are 
largely similar in those with and without diabetes. More-
over, therapies are mainly directed to control platelet 
activation and the fibrin network is not usually targeted 
unless there are additional pathologies such as atrial fibril-
lation or valvular heart disease. Therefore, in order to 
reduce residual vascular risk in diabetes, more effective 
anti-thrombotic treatment strategies are required.
This review will summarise current knowledge in fibrin 
network abnormalities in diabetes with special emphasis 
on fibrinolysis. The work will also explore diabetes-spe-
cific novel anti-thrombotic therapeutic targets aiming to 
reduce the unacceptably high risk of vascular disease in 
individuals with diabetes.
Clot formation and lysis
The formation of a fibrin clot is the final step in the 
atherothrombotic process, involving complex interac-
tions between platelets and plasma coagulation pro-
teins. After rupture of an atherosclerotic plaque, platelets 
adhere to the site of injury and become partially acti-
vated. Exposed tissue factor (TF) binds factor VII (FVII), 
promoting proteolysis and activation to FVIIa. The TF/
FVIIa complex activates FIX and FX resulting in the 
generation of FIXa and FXa, and the latter subsequently 
associates with cofactor FVa to form a prothrombinase 
complex, which converts prothrombin into thrombin 
[16]. The generated thrombin converts soluble fibrinogen 
into insoluble fibrin fibres. Thrombin also activates FXIII, 
a transglutaminase that crosslinks neighbouring fibrin 
fibres resulting in the formation of a branched fibrin clot 
structure, which is more resistant to lysis [17]. Activated 
FXIII (FXIIIa) crosslinks other proteins into the fibrin 
network, including plasmin inhibitor (PI) [18], thrombin 
activatable fibrinolysis inhibitor (TAFI) [19] and plasmi-
nogen activator inhibitor-2 (PAI-2) [20], further increas-
ing resistance of the clot to lysis. The coagulation cascade 
results in the formation of a fibrin mesh, with embedded 
erythrocytes and other cellular blood elements, which 
can occlude the vascular lumen, ultimately resulting in 
the acute complications of CVD, including myocardial 
infarction, stroke and critical limb ischaemia.
Normal physiology ensures a balance between fibrin 
clot formation and lysis in order to prevent widespread 
vascular occlusion or excessive bleeding. Plasmin is the 
enzyme responsible for fibrin breakdown (fibrinolysis) 
and is generated from plasminogen through the action of 
the serine protease tissue plasminogen activator (tPA), a 
product of endothelial cells [21]. The binding of tPA to 
fibrin increases the catalytic conversion of plasminogen 
to plasmin, while also localising the generation of plas-
min to the site of thrombus formation. Plasmin cleavage 
of fibrin generates new C-terminal lysine residues (addi-
tional tPA/plasminogen binding sites) within the fibrin 
network [22].
Several proteins prevent unregulated plasmin or plas-
minogen activator activity, thereby inhibiting excessive 
clot lysis. Plasminogen activator inhibitor (PAI-1) is pro-
duced by endothelial cells, platelets and adipose tissue. 
Like other serpins (serine protease inhibitors), PAI-1 
forms a stable  1:1 complex with tPA, thereby inhibiting 
its action [23]. Plasmin inhibitor (PI), another member of 
the serpin family, is the primary physiological inhibitor of 
plasmin. PI forms a stable inactive complex with plasmin, 
and can also be covalently cross-linked to fibrin making 
fibrin more resistant to lysis [24, 25]. Importantly, the 
fibrinolytic inhibitory properties of PI are significantly 
enhanced once the protein is cross-linked into the fibrin 
network. Thrombin activatable fibrinolysis inhibitor 
(TAFI) cleaves C-terminal lysine residues from partially 
degraded fibrin, decreasing the number of available plas-
minogen binding sites [26]. The main factors involved in 
clot formation and lysis are summarised in Fig. 1. Altered 
level and/or activity of these antifibrinolytic factors can 
modulate plasma clot lysis, and thereby thrombosis 
risk. Several studies have shown an association between 
hypofibrinolysis and increased thrombosis risk [27–30].
Factors involved in increased vascular risk 
in diabetes
Individuals with diabetes suffer from premature ath-
erosclerosis, a key contributing factor to increased car-
diovascular risk in this population. This is treated in the 
acute stage with revascularisation followed by preventa-
tive therapy in the long-term, including control of blood 
pressure, lipid and glucose levels. To control thrombosis 
risk following an acute vascular event, dual antiplate-
let therapy is usually used [31, 32], whereas treatment 
targeting the fibrin network is not considered except in 
cases of cardiac arrhythmias, valvular heart disease or 
history of venous thromboembolism. Factors leading to 
increased vascular events in diabetes and current treat-
ment modalities are summarised in Fig. 2.
The risk of aggressive anti-thrombotic therapy is 
increased bleeding which may negate any beneficial effect 
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of such therapy. A prime example is the TRITON study 
that has shown that the combination of prasugrel and 
aspirin is superior to clopidogrel and aspirin at reducing 
vascular ischaemia following myocardial infarction but 
there was an increased risk of bleeding with the former 
combination making widespread clinical use problematic 
[33]. Interestingly, patients with diabetes showed a ben-
efit with prasugrel/aspirin therapy without increased risk 
of bleeding suggesting altered response to anti-throm-
botic therapy in this population [32, 34].
Current anti‑thrombotic strategies: pitfalls
Reducing the thrombotic environment in arterial occlu-
sive disease relies mainly on antiplatelet therapy, using the 
cyclooxygenase inhibitor aspirin with or without P2Y12 
antagonists clopidogrel, prasugrel or ticagrelor. While 
all anti-platelet agents are likely to alter clot structure 
through indirect effects on platelet-dependent thrombin 
formation, aspirin is unique amongst anti-platelet agents 
as it directly alters clot structure and enhances fibrinoly-
sis, related, at least in part, to acetylation of fibrinogen. 
This makes aspirin an agent that independently targets 
both the cellular and protein phase of coagulation [35–
37]. It remains unclear, however, whether the pro-fibrino-
lytic effects of aspirin are important clinically and this 
remains an area for future research. It should be noted 
that other agents used in diabetes such as hypoglycaemia 
therapies, anti-hypertensive agents and statins may affect 
the thrombotic milieu, which is reviewed elsewhere and 
is not the focus of the current review [38].
Antithrombotic therapy in diabetes can be divided into 
primary prevention, which includes individuals without 
a previous history of vascular ischaemia, and secondary 
prevention in those who have had a vascular occlusive 
event. Until relatively recently, aspirin has been used for 
primary vascular protection in diabetes but a number of 
studies suggest a lack of significant success with such an 





















Fig. 1 Fibrin clot formation and lysis. Following vascular injury, tissue factor (TF) is released followed by a complex interaction between the cellular 
and protein arms of coagulation, resulting in activation of various coagulation factors, including FV, FVII, FIX and FX, culminating in the formation of 
thrombin, which converts soluble fibrinogen into a network of insoluble fibrin fibres. Thrombin also activates factor XIII (FXIII) to active FXIII (FXIIIa), 
which crosslinks the fibrin fibres and also incorporates antifibrinolytic proteins into the clot. Plasmin, derived from plasminogen by the action of 
tissue plasminogen activator (tPA), is the enzyme responsible for fibrin clot lysis, resulting in the generation of fibrin degradation products. The main 
inhibitors of fibrinolysis are plasmin inhibitor (PI) and plasminogen activator inhibitor (PAI-1)
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aspirin for primary vascular protection in subgroups of 
diabetes patients at a higher vascular risk, without clearly 
identifying these subgroups [8]. Until data becomes avail-
able from large primary prevention studies in diabetes, 
such as ASCEND (NCT00135226), routine aspirin ther-
apy for primary vascular protection in diabetes should be 
avoided and limited to individuals with multiple risk fac-
tors [40].
In individuals sustaining a coronary event, current 
guidelines advocate the use of dual antiplatelet therapy 
(DAT) to reduce thrombosis risk for a period of 1 year, 
followed by lifelong antiplatelet monotherapy [8]. Inter-
estingly, there is generally no differentiation between 
individuals with and without diabetes when it comes 
to DAT, despite the documented increased thrombotic 
environment in those with impaired glucose metabolism. 
Limited evidence suggests that prasugrel is more effective 
than clopidogrel at reducing further atherothrombosis in 
those with diabetes, however ticagrelor appears to have 
the best risk/benefit profile in those with and without 
diabetes, and therefore many centres use this agent for all 
patients regardless of glycaemic status [6, 41].
One year after the vascular event, P2Y12 inhibi-
tor therapy is usually stopped and patients continue on 
aspirin treatment. However, this approach is question-
able in diabetes as the efficacy of aspirin appears to be 
compromised, secondary to a number of factors includ-
ing increased platelet protein glycation and higher plate-
let turnover in diabetes [42]. Improving glycaemia may 
address the first point but the latter can only be over-
come by more frequent aspirin dosing. Indeed, a num-
ber of studies have shown a benefit in twice daily aspirin 
administration on platelet function profile, although out-
come studies employing this dosing regimen are lacking 
[43–45].
One striking observation of clinical studies aiming to 
reduce atherothrombosis risk is the concentration on 
antiplatelet therapy, generally ignoring the contribution 
of the protein arm of coagulation to the vascular ischae-
mic event. Early work has shown that warfarin, an agent 
that inhibits the production of various coagulation pro-
teins, can indeed improve outcome after arterial occlu-
sion. However this agent is associated with a narrow 
safe therapeutic window and the combination with anti-
platelet agents greatly increases bleeding risk [46]. More 
modern agents that affect coagulation proteins, such as 
FX inhibitor, show a greater promise although their use 
is still limited by the high bleeding risk when used with 
DAT [47].
FXII inhibitors offer a potential alternative antithrom-
botic strategy in diabetes that do not carry the bleeding 
risk associated with the aforementioned agents. FXII 
initiates the intrinsic coagulation pathway, however, 
FXII deficiency in mice is not associated with increased 
bleeding and offers protection against thrombosis. FXII 
inhibition may therefore be useful in instances involv-
ing activation of the intrinsic pathway (such as stent 
thrombosis) but may not be appropriate if the underlying 
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Fig. 2 Mechanisms for increased risk of vascular occlusive events in diabetes. Individuals with diabetes have premature atherosclerosis, which 
increases the risk of a coronary event. Individuals with coronary artery occlusion are treated with revascularisation in the acute stage followed 
by multifactorial therapy to halt the atherosclerotic process including control of blood pressure, blood glucose and lipid levels. Diabetes is also 
associated with an enhanced thrombotic milieu, secondary to increased activation of both platelets and coagulation factors. This is treated with 
anti-platelet therapy and the protein arm of coagulation is not usually targeted except in those with arrhythmias, valvular heart disease or a history 
of venous occlusion
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pathology is plaque rupture and future research in this 
area is certainly needed [48].
It should be remembered that acute fibrinolytic therapy 
has been successfully employed as a treatment for acute 
vascular occlusion and therefore strategies that facilitate 
clot lysis on a long-term basis have the potential to con-
trol the risk of atherothrombosis, particularly in condi-
tions characterised by impaired fibrinolysis.
Although the current review concentrates on macro-
vascular complications in diabetes, studies suggest that 
hypofibrinolysis is also associated with microvascular 
complications [49–51]. Therefore, addressing the hypofi-
brinolytic environment in diabetes may help not only by 
ameliorating macrovascular complications but also by 
reducing microvascular disease.
Factors involved in increased thrombosis risk in diabe-
tes and current anti-thrombotic strategies are summa-
rised in Table 1.
Mechanisms of hypofibrinolysis
Hypofibrinolysis is a key abnormality in individuals with 
diabetes and therefore modulation of this pathological 
process may offer therapeutic benefits. The main factors 
influencing fibrinolysis in diabetes include altered fibrin 
network structure, increased incorporation of antifi-
brinolytic proteins into the clot and compromised activ-
ity of the fibrinolytic system.
Clot structure in diabetes and factors contributing 
to altered clot phenotype
Compact fibrin networks with densely packed thin fibres 
are associated with increased risk of cardiovascular 
events [52–57], which may be due to reduced permeation 
of fibrinolytic enzymes into clots with these structures 
[58]. Although single thick fibrin fibres are cleaved at a 
slower rate than thin fibres, clots made from an increased 
number of more densely packed thin fibres are slower 
to lyse [59]. Additionally, thinner fibrin fibres support a 
slower rate of tPA-mediated plasmin generation than 
thick fibres, and a slower rate of fibrin digestion by plas-
min [60, 61]. It should be noted that increased incorpora-
tion of antifibrinolytic proteins into clots with compact 
structure further contributes to their resistance to break-
down and therefore the relationship between structure 
and lysis is more complex than initially envisaged [62].
Individuals with type 1 and type 2 diabetes have pro-
thrombotic compact fibrin networks which correlate 
with glycaemic control measured as HbA1c [63–66]. 
To complicate matters, glycaemia-independent factors, 
such as gender, can also determine fibrin clot structure 
with female patients exhibiting denser fibrin clots and 
prolonged lysis time [67]. This may be one of the mecha-
nisms contributing to the loss of cardiovascular protec-
tion in women who develop diabetes. Prolonged duration 
of T2DM (>5  years) is further associated with hypofi-
brinolysis and a prothrombotic clot phenotype, even if 
glycaemic control is adequate, adding yet more complex-
ity to studying fibrin network characteristics in this pop-
ulation [68]. These examples emphasise the heterogeneity 
in thrombosis potential in diabetes and highlight some of 
the challenges faced in developing safe and effective anti-
thrombotic agents in this condition.
Mechanisms for altered clot structure in diabetes
A number of mechanisms are responsible for altered clot 
structure in diabetes including quantitative and quali-
tative changes in coagulation factors as well as altered 
thrombin generation.
Plasma fibrinogen levels Previous studies have observed 
a relationship between elevated plasma levels of fibrino-
gen and the risk of CVD [69–72]. Evidence suggests that 
high plasma fibrinogen levels influence clot structure, by 
modulating network density and rigidity through increas-
ing fibre number and branch points. The increased risk 
of MI associated with elevated plasma fibrinogen levels 
Table 1 Current therapeutic interventions to reduce thrombosis risk in diabetes with their main limitations





Inflammatory changes resulting in 
endothelial dysfunction
Treated in the acute stage with revascularisation
Control of blood pressure, lipid and glucose levels in 
the long term
Mainly preventative





Altered levels of coagulation 
factors
Dual antiplatelet therapy (DAT) for 1 year following an 
acute coronary event
Lifelong platelet monotherapy after 1 year
Aspirin resistance in individuals with 
diabetes
Bleeding risk
No targeting of the fibrin network
Hypofibrinolysis Formation of more compact clots
Impaired fibrinolytic system
Not usually targeted
Agents that modulate the coagulation cascade,  
which are likely to affect fibrinolysis, are used in 
the presence of cardiac arrhythmias, valvular heart 
disease or venous thrombosis
Adding an agent that targets the 
fibrin network, particularly on a 
background of DAT, increases the 
risk of bleeding complications
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may be attributed, in part, to the formation of stiffer clots 
in these individuals [73]. In  vivo work has shown that 
elevated fibrinogen levels reduce time to vascular occlu-
sion, and increase clot fibrin content, network density and 
resistance to fibrinolysis in a murine model [74], linking 
changes in fibrin network to increased risk of thrombosis.
Plasma levels of fibrinogen in diabetes subjects has 
been a focus of much research, however, results are not 
always in agreement. The majority of, but not all, stud-
ies found elevated plasma fibrinogen levels in individuals 
with T2DM, and some reported higher levels in individu-
als with T1DM (summarised in [38]). The Rotterdam 
study found no significant difference in fibrinogen levels 
between individuals with T2DM and those with normal 
glucose metabolism after adjusting for age. However, 
plasma fibrinogen was significantly elevated in insulin-
treated T2DM patients, which may be due to poorer 
metabolic control in these individuals or longer disease 
duration [75].
Taken together, elevated fibrinogen levels appear to 
contribute to the compact fibrin networks observed in 
diabetes, at least in some patients.
Fibrinogen glycation Protein glycation is a post transla-
tional modification, the extent of which is determined by 
ambient glucose levels and the duration of protein expo-
sure. Glucose is able to bind non-enzymatically to fibrino-
gen by condensation of the carbonyl groups with amino 
groups on the fibrinogen molecule. Elevated glucose levels 
increase plasma protein glycation, including that of fibrin-
ogen [76–78], with a number of lysine residues becoming 
glycated [79]. This may contribute to more compact clots in 
diabetes, which in turn increases resistance to fibrinolysis 
[80, 81]. Moreover, as lysine is involved in the binding of 
tPA and plasminogen to fibrin, it is possible that fibrino-
gen glycation reduces binding of fibrinolytic proteins fur-
ther impairing clot lysis [81]. In support of this hypothesis, 
Dunn et al. observed a reduction in plasmin generation in 
individuals with diabetes, attributed to reduced tPA and 
plasminogen binding to fibrin [65].
Fibrinogen glycation in subjects with diabetes is modu-
lated by improving glycaemic control [76, 78, 82]. Pieters 
et  al. observed that improving glycaemia had no effect 
on the structure of fibrin clots made from T2DM plasma 
although an effect on clots made from purified fibrinogen 
was observed [80, 83]. The discrepancy between plasma 
and purified systems can be explained by the heteroge-
neity observed in plasma of patients with T2DM and the 
relatively small number of samples analysed.
It should be noted, however, that glycation is not the 
only post-translational modification of fibrinogen in 
diabetes [63]. Diabetes is also associated with elevated 
levels of reactive oxygen species [84], which are able to 
covalently modify protein structure, including that of 
fibrinogen [85]. Elevated levels of oxidative stress mark-
ers have been documented in T2DM, levels of which 
were inversely correlated with clot permeability and posi-
tively correlated with clot lysis time [86]. Therefore, both 
glycation and oxidation influence fibrin network proper-
ties in diabetes.
Thrombin generation Fibrin fibre diameter decreases 
with increasing thrombin levels. Low thrombin concentra-
tions (<1 nM, <0.1 U/ml) produce clots composed of loosely 
woven, thick fibres, whilst clots formed at high thrombin tend 
to be made up of thin, tightly packed fibrin strands which 
are relatively resistant to lysis [87, 88]. The concentration 
of thrombin observed during a coagulation reaction ranges 
from <1 to >500 nM [89], although low levels of thrombin 
(~2 nM) are sufficient for fibrin polymerisation [90].
Elevated thrombin generation has been reported in 
subjects with T2DM [68, 91–93]. In acute coronary 
syndrome, hyperglycaemia is associated with enhanced 
thrombin generation at the site of vascular injury and 
unfavourably altered clot features in patients with and 
without a history of diabetes [94]. Indeed, controlling 
glucose levels results in reduced thrombin generation 
[95]. On the other hand, over treatment of hyperglycae-
mia and precipitation of hypoglycaemia is associated 
with enhanced thrombin formation and the formation of 
more dense fibrin clots with resistance to lysis [96]. This 
indicates that both hyper and hypoglycaemia are pro-
thrombotic and caution should be exercised to avoid low 
blood glucose with hypoglycaemic therapy.
The mechanisms for enhanced thrombin genera-
tion in individuals with diabetes are not entirely clear. 
A study involving T1DM and T2DM patients showed 
that high levels of coagulation factors II,V,VII,VIII and 
X, coupled with low levels of anticoagulation factor pro-
tein C in diabetes are likely to be factors contributing to 
enhanced thrombin generation [91]. In another study, a 
modest elevation in thrombin generation in individuals 
with T2DM as well as those with impaired glucose toler-
ance was observed. In these individuals, central adiposity 
and related low grade inflammation, rather than glucose 
levels per se, were the likely explanations for enhanced 
thrombin generation [97].
Interaction between  inflammatory and  thrombotic pro‑
teins It is well established that low grade inflamma-
tion predisposes to atherothrombosis and a number 
of pathways have been implicated describing interac-
tions between inflammatory and thrombotic molecules, 
reviewed elsewhere [98–100]. For example, cytokines, 
important mediators of inflammation, can directly affect 
thrombosis risk by creating a hypercoagulable milieu 
Page 7 of 17Kearney et al. Cardiovasc Diabetol  (2017) 16:34 
and enhancing platelet reactivity [101]. Another exam-
ple is complement C3, a key regulator of inflammatory 
responses, a molecule that is incorporated into the clot 
and modulates fibrinolytic potential (discussed below).
Increased incorporation of anti‑fibrinolytic proteins
A potentially important but overlooked diabetes-related 
mechanism for hypofibrinolysis is increased incorpora-
tion of antifibrinolytic proteins into the clots, specifically 
complement C3 and PI.
Complement C3
Until recently, complement C3 was regarded as an 
inflammatory protein, but evidence suggests key interac-
tions between the complement and coagulation systems 
[102]. Two studies, using a proteomics approach, demon-
strated the presence of C3 and its metabolites in plasma 
clots [103, 104]. C3 protein can be covalently crosslinked 
to fibrin by FXIIIa, as well as weakly associating with the 
clot via non-covalent interactions [105, 106].
C3 binding/cross-linking into the fibrin network 
increases resistance of the clot to lysis [104]. Further work 
from our laboratory has demonstrated that incorporation 
of C3 into the fibrin clots of T1DM subjects has a greater 
effect on prolongation of clot lysis compared with clots 
from healthy controls [107]. The association between ele-
vated C3 plasma levels and prolonged clot lysis has also 
been observed in T2DM [108, 109]. In the study by Hess 
et  al. of 875 patients with T2DM, a regression analysis 
involving PAI-1, fibrinogen, C3 and CRP plasma levels, 
demonstrated that C3 was an independent predictor of 
fibrinolysis potential in contrast to CRP which failed to 
show an independent association with clot lysis.
The mechanisms for C3-induced compromise in clot 
lysis are not entirely clear but one may involve C3 inter-
ference with tPA and/or plasminogen binding sites on 
the fibrin network. Alternatively, C3 may affect the avail-
ability of plasmin to act on fibrin fibres, as C3 is a known 
substrate for plasmin [110]. Finally, the presence of ele-
vated levels of C3 in the fibrin clot may simply increase 
mechanical resistance of the clot to lysis [107]. From the 
therapeutic point of view, these findings suggest that tar-
geted disruption of C3-fibrinogen interaction may offer a 
diabetes-specific anti-thrombotic treatment strategy.
Plasmin inhibitor (PI)
Plasmin inhibitor (α2-antiplasmin, α2-plasmin inhibi-
tor) belongs to the serpin superfamily of proteins. PI is 
a key protein in blood haemostasis, as evidenced by the 
disorders caused by homozygous deficiency or by protein 
over-production. Congenital deficiency of PI results in a 
severe bleeding disorder [111, 112], whilst elevated lev-
els of PI are associated with an increased risk of first MI 
[113]. PI is the main biological inhibitor of plasmin, free 
PI is able to bind plasmin and form an irreversible stable 
complex, however, the fibrin-bound form of PI seems to 
be the main regulator of clot lysis [114]. Cross-linking of 
PI to the fibrin clot by FXIIIa has been shown to be a key 
determinant of resistance to lysis [25].
Agren et  al. found increased incorporation of PI into 
the fibrin network in individuals with T1DM, although 
these individuals exhibited a paradoxical reduction in 
clot lysis time, which the authors attributed to reduced 
PAI-1/fibrinogen levels [115]. An earlier study by Dunn 
et  al. found increased cross-linking of PI into the fibrin 
networks in T2DM, which increased resistance to lysis 
compared with controls [65]. This provides yet another 
diabetes-specific therapeutic target by manipulating PI 
incorporation into fibrin networks.
Compromised efficiency of the fibrinolytic system
A number of abnormalities in the fibrinolytic system 
have been reported in diabetes including elevated PAI-1 
and TAFI levels, and deranged plasminogen function.
TAFI in diabetes
There is some evidence to suggest that antifibrinolytic 
protein TAFI is upregulated in diabetes, which could 
contribute to the hypofibrinolytic state. Elevated plasma 
levels of TAFI are associated with increased risk of car-
diovascular diseases [116–120]. In diabetes, TAFI levels 
appear to correlate with HbA1c, indicating an associa-
tion between TAFI levels and poor glycaemic control 
[121]. Plasma concentration and activity of TAFI are sig-
nificantly increased in T2DM patients compared with 
healthy controls, particularly in obese patients [121]. 
TAFI levels have also been linked in T2DM to the pres-
ence of microvascular complications manifesting as 
microalbuminuria [122, 123]. However, Chudý et  al. 
found no significant difference in TAFI levels when nor-
moalbuminuric T2DM patients were compared with 
controls, and Yener and colleagues have demonstrated 
that TAFI levels do not increase in normotensive T2DM 
subjects without diabetic complications [123, 124]. To 
further complicate matters, others found TAFI levels to 
be decreased in nonobese T2DM individuals [125]. Taken 
together, these data reflect inconsistencies in the relation-
ship between TAFI and diabetes, which is perhaps related 
to the heterogeneity observed in these patients. There-
fore, studies including large numbers of diabetes patients 
are required, which would allow appropriate subgroup 
analysis, to fully understand the role of TAFI in diabetes.
PAI‑1 in diabetes
PAI-1 levels are associated with increased risk of CVD 
[126] with elevated protein levels found in young 
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(<45  years) survivors of myocardial infarction [127] and 
those with recurrent MI [128]. For many years, PAI-1, 
produced by endothelial cells and adipose tissue, has been 
regarded as the main inhibitor of fibrinolysis in diabetes. 
However, there is a difference between T1DM and T2DM 
as PAI-1 levels appear to be only elevated in the latter and 
correlate with glycaemic parameters as well as markers of 
insulin resistance [115, 129–133]. Hormonal (hyperinsu-
linemia) and metabolic (hyperglycemia and hypertriglycer-
idemia) derangements, typically found in T2DM patients, 
seem to have a role in elevated levels of PAI-1 levels in 
this population [130]. Stegenga et  al. demonstrated that 
in healthy subjects, hyperinsulinemia inhibits fibrinolysis, 
primarily by enhancing PAI-1 secretion, whilst hypergly-
caemia stimulates coagulation [134]. This group suggests 
that in T2DM subjects, the presence of both hyperinsu-
linemia and hyperglycaemia has a procoagulant effect with 
the simultaneous inhibition of fibrinolysis.
There is also an association of elevated PAI-1 levels and 
abdominal obesity as adipose tissue expresses PAI-1 and 
represents an important source of plasma PAI-1 in obese 
subjects [131–133]. This explains that the combination of 
T2DM and obesity contribute to an even greater eleva-
tion of PAI-1 than obesity or diabetes alone [135].
Plasminogen in diabetes
The hyperglycaemic environment in diabetes is respon-
sible for glycation of plasminogen, which compromises 
protein function. Plasminogen purified from plasma of 
individuals with T1DM has a decreased rate of conver-
sion to plasmin, and the plasmin generated has altered 
proteolytic activity, resulting in impaired fibrinolysis. 
Moreover, improving glycaemic control partially restores 
plasminogen conversion to plasmin and the activity 
of the enzyme, further emphasising the importance of 
maintaining good glycaemic control to reduce throm-
bosis risk. Interestingly, only a modest improvement 
in glycaemic control is enough to result in significant 
improvement in plasmin activity [136]. This suggests 
small improvements in glycaemic control translate clini-
cally into significant reduction in thrombosis risk.
Therefore, hyperglycaemia enhances thrombosis 
potential by increasing plasma levels of pro-coagulant 
and antifibrinolytic factors as well as modulating protein 
activity by introducing post-translational modifications 
in coagulation proteins. It should be noted, however, that 
not every single factor that modulates fibrinolysis has 
been comprehensively studied in diabetes, particularly 
in relation to the various subgroups of patients. There-
fore, in addition to developing agents that target the 
large number of anti-fibrinolytic proteins, future stud-
ies are required to understand the most relevant anti-
fibrinolytic strategy in the different subgroups of diabetes 
patients. This may indeed involve targeting multiple pro-
teins/pathways, particularly in the higher risk groups, to 
maximise clinical benefit.
A summary of the mechanisms involved in hypofi-
brinolysis in diabetes is provided in Fig. 3.
Current approaches to reduce hypofibrinolysis 
in diabetes
The potential role of various hypoglycaemic agents in 
thrombosis risk is beyond the scope of this review and 
will therefore concentrate on the effect of glycaemia per 
se on thrombosis potential.
Role of glycaemia
From the evidence presented above, it is clear that hyper-
glycaemia results in a prothrombotic and hypofibrinolytic 
environment. Moreover, relatively modest improvement 
in glycaemia appears to have a significant effect on fibrin 
network structure and/or resistance to lysis. It should be 
noted, however, that overtreatment of hyperglycaemia, 
and precipitation of hypoglycaemia, can also be pro-
thrombotic [137]. Studies have shown that hypoglycae-
mia results in elevated fibrinogen and PAI-1 levels [138]. 
This is consistent with our findings of impaired fibrinoly-
sis following hypoglycaemic clamps in diabetes individu-
als, with this enhanced prothrombotic milieu lasting for 
up to one week after the hypoglycaemic event [139]. The 
observation that both hyper and hypoglycaemia are pro-
thrombotic adds another dimension to the management 
of this risk factor, particularly as glucose levels can fluc-
tuate significantly in diabetes patients secondary to daily 
activities, diet and hypoglycaemic therapies.
Taken together, the above findings may offer mechanis-
tic explanations for the disappointing clinical outcome 
trials investigating the role for tight glycaemic control in 
reduction of vascular ischaemic events in diabetes [140]. 
It is plausible that mild improvement in glucose is all that 
is needed to control the prothrombotic environment in 
diabetes. Trying to achieve too tight control runs the risk 
of repeated hypoglycaemia, predisposing to an enhanced 
thrombotic environment, thus negating any beneficial 
effect for reducing blood glucose levels.
From the practical point of view, using agents that are 
less likely to cause hypoglycaemia may have the advan-
tage of reducing the thrombotic environment in diabe-
tes and protecting against vascular ischaemic events. We 
have limited evidence to suggest that agents that do not 
cause hypoglycaemia, such as metformin, pioglitazone, 
empagliflozin and liraglutide are associated with favour-
able cardiovascular profile [141–144]. In contrast, agents 
that may result in hypoglycaemia such as sulphonylurea 
and insulin have been linked to increased cardiovascular 
risk [145]. However, there are complexities encountered 
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in dissecting out the effect of each agent, given that most 
high risk individuals are on combination therapy, and 
therefore further research in this area is needed before 
concrete conclusions can be made.
Potential diabetes–specific therapeutic targets to reduce 
hypofibrinolysis
Given that diabetes is associated with increased plasma 
levels of PAI-1 and TAFI, and increased incorporation 
of PI and C3 into the clot, targeting these proteins may 
alleviate the hypofibrinolytic environment, consequently 
decreasing atherothrombotic risk.
TAFI as a drug target
TAFI circulates in an inactive zymogen form and is acti-
vated by thrombin, plasmin, or the thrombin-thrombo-
modulin complex. Activated TAFI cleaves C-terminal 
lysine residues from partially degraded fibrin, which are 
critical for the binding of plasminogen and as a result, 
plasmin generation is reduced [146].
Inhibition of TAFI was considered as a therapeutic 
strategy in thrombotic disorders but only a limited 
number of drug candidates have made it to clinical 
trials, which were then discontinued (reviewed else-



















Compact clot and 
resistance to fibrinolysis
Healthy fibrin clot
Fig. 3 Mechanisms involved in hypofibrinolysis in diabetes. The main factors influencing hypofibrinolysis in diabetes include altered fibrin network 
structure and an impaired fibrinolytic system. Factors contributing to altered clot structure include elevated levels of thrombin, and both quantita-
tive and qualitative alterations in fibrinogen, including glycation and oxidation of fibrinogen molecules. Elevated levels of plasminogen activator 
inhibitor (PAI-1), glycation of plasminogen and increased incorporation of antifibrinolytic proteins plasmin inhibitor (PI) and complement C3 into 
clots in individuals with diabetes all contribute to impaired fibrinolysis. Levels of thrombin activatable fibrinolysis inhibitor (TAFI) can be raised in 
diabetes but studies are conflicting with some showing no change. Scale bar 5 μm. ↑, increase; →, no change
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the TAFI-inhibitory ability of TAFI-derived peptides 
on the protein’s activation and activity. Peptides with 
the ability to prevent TAFI activation, and inhibit 
TAFIa activity directly were identified [149]. An alter-
native anti-TAFI approach by Buelens et al. created a 
panel of inhibitory nanobodies effective against the 
various modes of TAFI activation and activity. Nano-
bodies are single domain antibodies from the sera of 
members of the Camilidae family which have advan-
tageous properties such as low immunogenicity and 
high affinity, solubility and stability [150]. Two nano-
bodies showed a potent profibrinolytic effect in an 
in vitro clot lysis assay and their interaction with TAFI 
was later characterised using X-ray crystallography. 
One nanobody was shown to bind close to the TAFI 
activation site, and the other close to a possible throm-
bomodulin binding site. These findings explained the 
interference of the two nanobodies with TAFI activa-
tion, and thrombin-thrombomodulin-mediated acti-
vation, respectively [151]. Although these studies are 
promising and shed light on the mechanistic proper-
ties of TAFI-inhibitory compounds, in  vivo data are 
lacking.
PAI‑1 as a drug target
PAI-1 is present in an active and a latent state in vivo 
with the active form having high affinity for vitronec-
tin, which binds PAI-1 in the blood [152]. PAI-1 has a 
relatively short half-life of  ~  1  h in physiological con-
ditions [153, 154] which some may argue would limit 
its use as a therapeutic target. The counter-argument, 
however, is that the short half-life makes it a suitable 
target for acute vascular thrombosis. Several PAI-1 
inhibitors have been tested in vivo and in vitro and dis-
played inhibitory activity, but to date no PAI-1 inhibi-
tor is clinically available. Prevention of cellular PAI-1 
biosynthesis is another strategy which has been par-
tially explored.
Small molecule inhibitors of PAI‑1 synthesis
Small molecule inhibitors of PAI-1 synthesis include 
synthetic and natural products such as niacin, fibrates 
and butadiene derivatives (reviewed in [114]). How-
ever, these compounds are not PAI-1 specific, hav-
ing other metabolic effects and therefore dissecting 
out their role on clinical outcome is difficult. Also, 
in  vitro studies do not always translate into in  vivo 
benefits and an example of the disparity can be seen 
with fibrate use; a recent meta-analysis has reported 
that fibrates do not cause a decrease in PAI-1 levels or 
activity, despite their in vitro effects [155]. Therefore, 
direct PAI-1 inhibitors may have an advantage by tar-
geting plasma PAI-1.
Direct PAI‑1 inhibitors
Antibodies against  PAI‑1 There have been numerous 
attempts at inhibiting PAI-1 with antibodies, reviewed 
elsewhere [148, 156] but none have been taken forward 
to the clinical arena. Recent work in mouse models of 
thrombotic stroke have shown that simultaneous inhi-
bition of PAI-1 and TAFI with a bispecific antibody 
results in a significant enhancement of fibrinolysis in 
mice, without increased bleeding [157]. To dissect out 
the contribution of PAI-1 inhibition and TAFI inhibi-
tion during ischaemic stroke, Denorme et al. used mon-
oclonal antibodies to identify the effect of inhibiting 
each of these antifibrinolytic factors. In a mouse model 
of transient middle cerebral artery occlusion, inhibition 
of TAFI or PAI-1 significantly decreased fibrin(ogen) 
deposition in the ischaemic brain, thereby improv-
ing reperfusion, but the combined inhibition had an 
additive beneficial effect [158]. PAI-1 inhibition is also 
possible with nanobodies, which was demonstrated 
by Zhou et  al. who used nanobodies against PAI-1 to 
inhibit profibrinolytic activity in an in  vitro clot lysis 
assay [159]. Clearly there are some promising benefits 
in the inhibition of PAI-1 with antibodies, which merit 
further in vitro and in vivo analysis.
Other PAI‑1 inhibitors A number of groups have 
employed different methods for identification of PAI-1 
inhibitors, including high throughput and in silico screen-
ing, reviewed extensively elsewhere [114, 160]. Using this 
methodology, Elokdah and colleagues identified Tiplax-
tinin as a potent and selective PAI-1 inhibitor [161], which 
became one of the most studied PAI-1 inhibitors to date. 
Tiplaxtinin binds specifically to the active conformation 
of PAI-1, its activity, however, is blocked by vitronectin, 
suggesting their binding sites on PAI-1 are overlapping 
[162]. In a canine model of occlusive thrombus forma-
tion, administration of Tiplaxtinin caused spontaneous 
coronary reperfusion, indicating active fibrinolysis. When 
Tiplaxtinin was administered to rats following induction 
of an occlusive arterial thrombosis, thrombus weight was 
reduced and blood flow facilitated with increased occlu-
sion time in the affected vessel. In both these models, 
there were no side effects reported such as changes in 
heart rate, blood pressure or increased bleeding [161].
Other small molecule inhibitors have been identified, 
such as ZK4044 which binds directly to PAI-1, prevent-
ing its interaction with target proteases [163], WAY-
140312 which binds and inactivates PAI-1 [164], and 
S35225 a benzothiophene derivative which, in contrast to 
WAY-140312 and Tiplaxtinin is able to inhibit PAI-1 in 
the presence of vitronectin [165]. Despite promising can-
didates, there has been no progression of PAI-1 inhibi-
tors to clinical trials in man [166]. One explanation for 
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this lack of progress could be the unique structural prop-
erties of PAI-1. Crystallographic data of PAI-1 in com-
plex with vitronectin is still incomplete and thus hampers 
rational design of small molecules able to bind and inac-
tivate PAI-1 in its vitronectin-bound state. Additionally, 
the active form of PAI-1 is yet to be crystallised due to 
its instability, and the mechanism by which active PAI-1 
transitions to its latent form is not fully understood. 
Although numerous PAI-1 inhibitory compounds have 
been investigated, for many, their mechanism of action 
remains elusive, providing yet another obstacle in the 
clinical application of PAI-1 inhibitors.
Plasmin inhibitor as a drug target
The reported increased incorporation of PI into fibrin 
clots in diabetes renders this protein a potential diabetes-
specific therapeutic target. Numerous attempts at target-
ing PI have been made, including the use of antibodies 
and mutant forms of the protein.
Antibodies
Kumada et  al. reported that repeated injection of poly-
clonal anti-PI F(ab’)2 fragments reduced circulating PI lev-
els and led to an acceleration of thrombolysis by enhancing 
fibrinolytic activity [167]. A more targeted approach by 
Sakata et  al. saw the creation of a monoclonal antibody 
that was able to interfere with the formation of PI-plasmin 
complexes by recognising an epitope either in or close to 
the reactive site of PI. This antibody, termed JTPI-1, was 
able to increase the effectiveness of tPA-mediated clot lysis 
in plasma [168]. Similarly, an antibody capable of inhibit-
ing both PI in plasma and clot-bound PI caused spon-
taneous clot lysis and also enhanced tPA-mediated clot 
lysis in  vitro [169]. An extension of these studies in  vivo 
by Reed et al. used an antibody targeted to clot-bound PI, 
which was found to enhance lysis of a human clot in a rab-
bit jugular vein thrombosis model [170].
Plasmin inhibitor mutants
Arginine residue 364 is the main reactive site on PI, 
which forms a covalent bond with the active site serine 
in plasmin, resulting in an inactive protease-inhibitor 
complex [171, 172]. Lee et al. generated PI with a chemi-
cally modified reactive site arginine [173] and an Arg-Ala 
mutant [174]. Both of these modified PI molecules lost 
their plasmin-inhibitory activity, but still competed with 
native PI for crosslinking into the fibrin clot by FXIIIa, 
thereby enhancing fibrinolysis.
N and C terminal peptides of plasmin inhibitor
The N-terminal region of PI is crucial for cross-linking 
to fibrinogen [175, 176], whereas the C-terminal of the 
protein mediates interaction with plasmin [177]. Kimura 
et  al. created a 12 residue synthetic N-terminal peptide 
of PI that was able to reduce incorporation of native PI 
into fibrin networks by FXIIIa in  vitro. Cross-linking of 
the synthetic peptide to fibrin accelerated spontaneous as 
well as tPA-induced fibrinolysis. The quantity of native PI 
cross-linked to fibrin was proportionally reduced by the 
presence of the synthetic N-terminal peptide, indicating 
PI specificity of the synthetic peptide [178].
Others attempted to use the C-terminus of PI as a 
means of enhancing fibrinolysis. A 26 amino acid pep-
tide composed of the carboxy terminal region of PI was 
found to enhance in  vitro fibrin clot lysis by increasing 
conversion of plasminogen to plasmin approximately 
fivefold [179]. Similarly, Udvardy et  al. observed that a 
peptide containing the 26 amino acid C-terminal of PI, 
coupled with RGD (Arg-Gly-Asp) peptide was capable 
of simultaneously promoting fibrinolysis and inhibiting 
platelet aggregation. Fibrinogen RGD sequence mediates 
its interaction with platelets, RGD peptides are able to 
disrupt fibrinogen-platelet interactions and have platelet 
inhibitory effects, as observed in this study [180].
Inhibition of plasmin inhibitor cleavage
Plasmin inhibitor is present in two forms in human 
plasma, a 464-residue protein with methionine at the 
N-terminus (Met-PI) and a truncated 452-residue pro-
tein with asparagine at its N-terminus (Asn-PI). Human 
plasma contains around 30% Met-PI and 70% Asn-PI 
form. Asn-PI, formed from Met-PI by the action of anti-
plasmin cleaving enzyme (APCE), is more rapidly cross-
linked to fibrin by FXIIIa [181–184]. APCE represents 
a therapeutic target, since inhibition of this enzyme 
could reduce circulating levels of Asn-PI and therefore 
decrease incorporation of PI into the fibrin clot. Indeed, 
Lee et al. observed an enhancement of plasma clot lysis 
when APCE was inhibited in vitro [185] but in vivo stud-
ies are lacking.
Despite promising preliminary data, none of these 
approaches of PI-related therapeutic targets have been 
clinically adopted, indicating that translating in  vitro 
findings, and even animal work, into application in man 
is difficult and more complex than initially envisaged.
Complement C3 as a drug target
Therapeutic intervention in the complement system has 
been recognised as a potential strategy for the treatment 
of a series of inflammatory and autoimmune diseases 
[186, 187] whilst the role of C3 in fibrinolysis has yet to 
be widely recognised as an antithrombotic therapeutic 
target. Early work has shown that one approach in modu-
lating the antifibrinolytic action of C3 has involved using 
a phage display system of small conformational peptides 
termed Adhirons. One Adhiron was identified which 
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abolished C3-induced prolongation of fibrin clot lysis by 
interfering with the C3-fibrinogen interaction. Impor-
tantly, this Adhiron, being specific for fibrinogen poten-
tially avoids targeting of C3 systemically, narrowing the 
therapeutic window and lessening the risk of off-target 
effects [188]. It remains to be seen whether this approach 
proves to be suitable for future clinical application.
Potential future strategies to enhance the fibrinolytic 
process, and reduce thrombosis risk in diabetes are sum-
marised in Table 2.
Conclusions/summary
Despite advances in treatment, vascular mortality in 
patients with diabetes remains unacceptably high, which 
is partly related to the enhanced thrombotic environment 
that is not fully controlled with current anti-platelet ther-
apies. Rather than developing more effective anti-platelet 
agents, which runs the risk of bleeding complications, an 
alternative approach is to target the hypofibrinolytic state 
in diabetes, a key abnormality in this condition. There-
fore, understanding the mechanisms for increased fibrin-
related thrombosis risk in diabetes is key to develop 
effective and safe novel antithrombotic therapies.
Diabetes is associated with both quantitative and quali-
tative changes in clotting factors resulting in denser fibrin 
networks that are more difficult to lyse. In addition to 
changes in clot structure, diabetes directly impairs the 
function of the fibrinolytic system and shows increased 
incorporation of anti-fibrinolytic proteins into the clot. 
More specifically, recent studies have shown increased 
incorporation of PI and complement C3 into diabetes 
clots, which compromise fibrin clot lysis. The increased 
incorporation of anti-fibrinolytic proteins into fibrin net-
works represents a novel diabetes-specific mechanistic 
pathway that may be a target for a new generation of 
anti-thrombotic agents.
In summary, targeting alternative and diabetes-specific 
thrombotic pathways may be the best approach to reduce 
the residual thrombosis risk in diabetes and improve vas-
cular outcome in this population.
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